These findings underscore the critical role of intracellular HMGB1 in modulating PD-L1 expression via the JAK2–STAT3 signaling pathways in breast cancer and suggest that targeting HMGB1 translocation is a promising strategy for breast cancer treatment. This evidence concerns the gene JAK2 and breast cancer.